Navigation Links
Lawson research shows Canadians don't believe their eyes
Date:9/29/2011

LONDON, ON - Glaucoma is the second leading cause of blindness worldwide. Although it can be treated, new research shows Canadians may not be doing enough to protect themselves. According to a new study by Lawson Health Research Institute's Dr. Cindy Hutnik, many Canadian glaucoma patients are not screened until the disease has reached moderate or advanced stages.

Glaucoma is known as the "silent thief of sight." It slowly and irreversibly destroys the optic nerve so slowly, in fact, that many people don't realize they have glaucoma until it reaches advanced stages. To maintain eye health, preventive screening is vital. Yet despite a spectrum of known risk factors, it appears many Canadians are not checking for them.

In a multi-centre study, Hutnik and her colleagues examined the risk factors shared by 404 newly diagnosed patients across 18 Canadian locations. Each was assessed for demographic information, medical history, and ocular family history, as well as a complete eye exam. Results were largely consistent with the international standards, confirming older age, structural abnormalities and deterioration, and high intraocular pressure as leading glaucoma risk factors. In a surprising twist, however, 48% of these new diagnoses nearly half were already at moderate to advanced stages.

It is not clear why Canadians are not screening for glaucoma earlier. Researchers suspect the slow disease progression may not project the same urgency as, for example, a broken limb. The additional cost of screening, which is not covered by OHIP, may also be a deterrent. Researchers have even suggested that available screening measures may not be sensitive enough to detect the complex spectrum of risk factors at early stages. While investigation continues, Dr. Hutnik urges Canadians to keep a close eye on the situation.

"Almost half to two-thirds of your optic nerve is dead before you even get a visual field defect," she explains. "If you're late getting your clinical screening test, the nerve has been dying for a long time and once it's dead, it's dead. You can only prevent it from getting worse."


'/>"/>

Contact: Sonya Gilpin
sonya.gilpin@lawsonresearch.com
519-685-8500 x75852
Lawson Health Research Institute
Source:Eurekalert

Related biology news :

1. Professor Dr. Alexander (Sandy) Lawson is awarded the 2011 Herman Skolnik Award
2. Lawson researchers take control of cancer
3. Lawson researchers share in $2.2 million grant
4. Wistar Institute researcher receives New Innovator award from NIH
5. NC State researchers get to root of parasite genome
6. White Mountain Research Station to host climate change conference
7. Stevens awarded $1M for advanced biofuels research
8. Researchers find animal with ability to survive climate change
9. Researchers find an essential gene for forming ears of corn
10. Researchers note differences between people and animals on calorie restriction
11. Researcher working on destruction of chemical weapons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- ... platform that is designed to enhance fraud detection ... release in the RSA Fraud & Risk Intelligence ... organizations to leverage additional insights from internal and ... to better protect their customers from targeted cybercrime ...
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
(Date:2/7/2017)... Ind. , Feb. 7, 2017 Zimmer ... leader in musculoskeletal healthcare, will present at the LEERINK ... New York Palace Hotel on Wednesday, February 15, 2017 ... live webcast of the presentation can be accessed at ... replay following the conference via Zimmer Biomet,s Investor Relations ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... 27, 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; ... Friday, February 24, 2017 a total of 10,672,750 common share ... per common share. Proceeds from the exercise of these warrants ... Treasury.   ... "We are grateful for this expression of confidence by our ...
(Date:2/27/2017)... and HAMILTON, Bermuda ... (NASDAQ: ADXS ) and ... companies focused on developing cancer immunotherapies, today announced ... develop a novel cancer immunotherapy agent using Advaxis, ... SELLAS, patented WT1 targeted heteroclitic peptide antigen mixture ...
(Date:2/27/2017)... ... ... The Catalyst Midwest premix manufacturing facility has been certified as organic, ... label organic services. , The first organic product is Organic 18 Percent Layer Feed, ... Marketing, which owns the facility. , Catalyst already has received the Safe Feed/Safe ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... can be safely completed in an ambulatory surgery center (ASC) with satisfactory clinical ... and previous two-year TDR studies. , Jake Lubinski, president of AxioMed, commented ...
Breaking Biology Technology: